Dr. Salvatore La Fata, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2020 Sheffield Dr, Clovis, NM 88101 Phone: 505-762-4507 Fax: 505-762-7220 |
Basil A Anaele, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1521 W 13th St, Clovis, NM 88101 Phone: 575-769-0888 Fax: 575-763-9154 |
Adora Anudu, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2200 W 21st St, Clovis, NM 88101 Phone: 575-769-7577 Fax: 575-769-6329 |
David B Vickers, MD Pediatrics Medicare: Medicare Enrolled Practice Location: Plains Regional Medical Group, 2200 W 21st St, Clovis, NM 88101 Phone: 575-769-7577 Fax: 575-769-7595 |
Dr. Thien Tien Luu, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2000 W 21st St, #e-2, Clovis, NM 88101 Phone: 575-762-3726 Fax: 575-762-3727 |
Kathryn E Winters, MD Pediatrics Medicare: Medicare Enrolled Practice Location: Plains Regional Medical Group, 2200 W 21st St, Clovis, NM 88101 Phone: 575-769-7577 Fax: 575-769-7595 |
News Archive
A pioneering scalp cooling treatment that prevents alopecia in early stage breast cancer patients undergoing chemotherapy will be showcased at the 15th St. Gallen International Breast Cancer Conference, Vienna.
In a SciDev.Net editorial, David Dickson, director of SciDev.Net, examines progress towards the Millennium Development Goal (MDG) targets, highlighting their usefulness as well as their shortcomings. "The value of the MDGs lies in the way they have acted as both a carrot and a stick to focus the efforts of both development agencies and governments of developing countries," according to Dickson, who writes that "the curse of the MDGs is that they focus on relatively short-term, concrete objectives, and lack sufficient 'buy-in' from the very countries they are intended to help.
National Institutes of Health scientists have filled a research gap by developing a laboratory model to study ticks that transmit flaviviruses, such as Powassan virus. Powassan virus was implicated in the death of a New York man earlier this year.
Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).
Julie Lopez, 21, has been tested regularly for sexually transmitted diseases since she was a teenager. But when Lopez first asked her primary care doctor about screening, he reacted with surprise, she said.
› Verified 4 days ago